Leerink Partnrs Forecasts Increased Earnings for NovoCure

NovoCure Limited (NASDAQ:NVCR) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of NovoCure in a note issued to investors on Monday, December 2nd. Leerink Partnrs analyst J. Chang now expects that the medical equipment provider will post earnings of ($1.92) per share for the year, up from their previous estimate of ($1.93). The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share.

NVCR has been the subject of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price (up previously from $30.00) on shares of NovoCure in a research report on Monday. Wedbush restated a “neutral” rating and issued a $29.00 price target (up from $24.00) on shares of NovoCure in a research report on Monday. Finally, Evercore ISI raised shares of NovoCure from an “in-line” rating to an “outperform” rating and lifted their price target for the company from $18.00 to $30.00 in a report on Monday. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, NovoCure currently has an average rating of “Moderate Buy” and a consensus price target of $30.33.

NovoCure Stock Down 9.0 %

Shares of NASDAQ:NVCR opened at $26.60 on Thursday. The firm has a market cap of $2.88 billion, a PE ratio of -19.00 and a beta of 0.75. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27. NovoCure has a 12-month low of $11.66 and a 12-month high of $32.60. The company has a fifty day simple moving average of $17.68 and a 200 day simple moving average of $18.64.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. NovoCure had a negative net margin of 25.93% and a negative return on equity of 41.48%. The firm had revenue of $155.10 million for the quarter, compared to analyst estimates of $143.95 million. During the same quarter in the previous year, the business posted ($0.46) EPS. The firm’s revenue was up 21.8% compared to the same quarter last year.

Institutional Trading of NovoCure

A number of hedge funds have recently made changes to their positions in NVCR. Franklin Resources Inc. increased its position in NovoCure by 222.6% during the third quarter. Franklin Resources Inc. now owns 180,853 shares of the medical equipment provider’s stock worth $2,904,000 after buying an additional 124,793 shares during the last quarter. Tidal Investments LLC boosted its stake in shares of NovoCure by 4.6% during the 3rd quarter. Tidal Investments LLC now owns 55,756 shares of the medical equipment provider’s stock worth $871,000 after acquiring an additional 2,465 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of NovoCure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,405,257 shares of the medical equipment provider’s stock valued at $37,601,000 after acquiring an additional 29,871 shares during the last quarter. Weiss Asset Management LP bought a new position in shares of NovoCure in the 3rd quarter valued at approximately $735,000. Finally, IHT Wealth Management LLC bought a new position in shares of NovoCure in the 3rd quarter valued at approximately $180,000. 84.61% of the stock is owned by hedge funds and other institutional investors.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.